- Home
- NCDL vs PSTX Comparison
NCDL vs PSTX Comparison
Compare NCDL & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- PSTX
- Stock Information
- Founded
- NCDL 2019
- PSTX 2014
- Country
- NCDL United States
- PSTX United States
- Employees
- NCDL N/A
- PSTX N/A
- Industry
- NCDL
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCDL
- PSTX Health Care
- Exchange
- NCDL NYSE
- PSTX Nasdaq
- Market Cap
- NCDL 937.5M
- PSTX 909.4M
- IPO Year
- NCDL N/A
- PSTX 2020
- Fundamental
- Price
- NCDL $16.87
- PSTX $9.45
- Analyst Decision
- NCDL Buy
- PSTX Hold
- Analyst Count
- NCDL 6
- PSTX 3
- Target Price
- NCDL $18.33
- PSTX $9.00
- AVG Volume (30 Days)
- NCDL 351.4K
- PSTX 2.7M
- Earning Date
- NCDL 11-07-2024
- PSTX 11-07-2024
- Dividend Yield
- NCDL 7.98%
- PSTX N/A
- EPS Growth
- NCDL N/A
- PSTX N/A
- EPS
- NCDL N/A
- PSTX N/A
- Revenue
- NCDL N/A
- PSTX $150,858,000.00
- Revenue This Year
- NCDL N/A
- PSTX $131.92
- Revenue Next Year
- NCDL N/A
- PSTX N/A
- P/E Ratio
- NCDL N/A
- PSTX N/A
- Revenue Growth
- NCDL N/A
- PSTX 203.18
- 52 Week Low
- NCDL $16.00
- PSTX $1.87
- 52 Week High
- NCDL $18.10
- PSTX $9.58
- Technical
- Relative Strength Index (RSI)
- NCDL 40.01
- PSTX 86.05
- Support Level
- NCDL $16.75
- PSTX $9.35
- Resistance Level
- NCDL $17.37
- PSTX $9.56
- Average True Range (ATR)
- NCDL 0.20
- PSTX 0.10
- MACD
- NCDL -0.05
- PSTX -0.17
- Stochastic Oscillator
- NCDL 17.91
- PSTX 56.67
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.